1. Home
  2. TYGO vs MOLN Comparison

TYGO vs MOLN Comparison

Compare TYGO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tigo Energy Inc.

TYGO

Tigo Energy Inc.

HOLD

Current Price

$1.17

Market Cap

129.0M

Sector

Technology

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.13

Market Cap

154.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYGO
MOLN
Founded
2007
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
129.0M
154.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
TYGO
MOLN
Price
$1.17
$4.13
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$6.00
$8.38
AVG Volume (30 Days)
1.7M
1.0K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
97.12
N/A
EPS
0.01
N/A
Revenue
$103,536,000.00
N/A
Revenue This Year
$30.78
N/A
Revenue Next Year
$21.68
$374.07
P/E Ratio
$123.00
N/A
Revenue Growth
91.68
N/A
52 Week Low
$0.93
$3.46
52 Week High
$5.33
$5.36

Technical Indicators

Market Signals
Indicator
TYGO
MOLN
Relative Strength Index (RSI) 28.84 54.69
Support Level N/A $3.91
Resistance Level $1.73 $4.13
Average True Range (ATR) 0.16 0.05
MACD -0.01 0.02
Stochastic Oscillator 20.26 71.41

Price Performance

Historical Comparison
TYGO
MOLN

About TYGO Tigo Energy Inc.

Tigo Energy Inc provides solar and energy storage solutions, including module level power electronics (MLPE) designed to maximize the energy output of individual solar modules, delivering more energy, active management, and enhanced safety for utility, commercial, and residential solar arrays. By combining its MLPE and solar optimizer technology with intelligent, cloud-based software capabilities, the Company enables developed energy monitoring, system diagnostics, and real-time control. Geographically the company generates revenue from EMEA, Americas, and APAC.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: